Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China¶
Why this mattered¶
This paper mattered because it converted an alarming cluster of unexplained pneumonia into a clinically legible disease. From 41 laboratory-confirmed hospitalized patients in Wuhan, Huang and colleagues described the early syndrome that would become COVID-19: fever and cough, frequent bilateral pneumonia, lymphopenia, progression in some patients to dyspnea, acute respiratory distress syndrome, ICU admission, and death. Its sample was small and biased toward severe hospitalized illness, so it did not define the full infection-fatality risk or community spectrum. But it gave clinicians and public-health authorities one of the first concrete maps of what severe SARS-CoV-2 infection looked like at the bedside.
The paradigm shift was that the new coronavirus could no longer be treated as only a virological curiosity or localized outbreak signal. The paper showed a human disease course with reproducible clinical, radiographic, laboratory, and outcome patterns, including multi-organ complications and inflammatory markers associated with ICU-level illness. That made systematic triage, cohort comparison, severity scoring, respiratory-support planning, and therapeutic hypothesis generation newly possible at global speed.
Subsequent breakthroughs built directly on this early clinical framing. Larger cohorts refined risk factors and mortality estimates; intensive-care studies focused on oxygenation, ARDS management, thrombosis, and organ injury; immunology and trial programs pursued the inflammatory-dysregulation signal that helped lead to corticosteroid and immunomodulator strategies in severe disease. The paper did not solve COVID-19, but it supplied the first widely cited clinical scaffold on which the pandemic’s diagnostics, hospital protocols, prognostic studies, and randomized treatment trials could be organized.
Abstract¶
(no abstract available)
Related¶
- cite → Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia — The Wuhan COVID-19 clinical report cites the 2012 MERS coronavirus isolation paper as prior evidence that novel coronaviruses can cause severe human pneumonia.
- cite ← SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor — The SARS-CoV-2 entry paper links its ACE2/TMPRSS2 mechanism study to early clinical characterization of COVID-19 patients in Wuhan.
- cite ← Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein — The spike glycoprotein paper uses early Wuhan clinical reports to frame SARS-CoV-2 as the cause of severe human pneumonia.
- cite ← Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation — The spike-structure paper cites early Wuhan clinical reports to establish COVID-19 as the disease context for SARS-CoV-2 structural analysis.
- cite ← Dexamethasone in Hospitalized Patients with Covid-19. — The dexamethasone COVID-19 trial cited early Wuhan clinical features to contextualize severe hospitalized disease and respiratory outcomes.
- cite ← Dexamethasone in Hospitalized Patients with Covid-19 — The dexamethasone trial targets severe hospitalized Covid-19 illness described in early Wuhan clinical-feature reports.
- cite ← Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding — The genomic characterization paper cites the Wuhan clinical-features study to connect viral sequence findings with early patient presentation.
- enables ← Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia — Isolation and clinical characterization of MERS-CoV established coronavirus pneumonia investigation methods later applied to the Wuhan 2019-nCoV patient cohort.